Financhill
Sell
8

MRNA Quote, Financials, Valuation and Earnings

Last price:
$39.60
Seasonality move :
6.66%
Day range:
$38.52 - $40.34
52-week range:
$35.80 - $170.47
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.03x
P/B ratio:
1.28x
Volume:
5M
Avg. volume:
9.9M
1-year change:
-58.28%
Market cap:
$15.2B
Revenue:
$6.8B
EPS (TTM):
-$5.82

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
MRNA
Moderna
$1.2B -$1.94 -63.53% -79.68% $127.09
BIIB
Biogen
$2.4B $3.79 1.22% 101.89% $242.83
LLY
Eli Lilly and
$12.1B $1.47 49.68% 124.93% $984.05
MRK
Merck &
$16.5B $1.57 5.76% -15.62% $128.73
NVAX
Novavax
$73.8M -$0.75 -64.12% -56.12% $16.00
PFE
Pfizer
$14.9B $0.61 27.51% 12.4% $31.86
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
MRNA
Moderna
$39.59 $127.09 $15.2B -- $0.00 0% 3.03x
BIIB
Biogen
$149.38 $242.83 $21.8B 13.49x $0.00 0% 2.27x
LLY
Eli Lilly and
$796.28 $984.05 $755.9B 86.08x $1.30 0.65% 17.62x
MRK
Merck &
$99.37 $128.73 $251.4B 20.83x $0.81 3.14% 4.00x
NVAX
Novavax
$8.64 $16.00 $1.4B -- $0.00 0% 1.50x
PFE
Pfizer
$26.71 $31.86 $151.4B 36.09x $0.42 6.29% 2.56x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
MRNA
Moderna
-- 0.826 -- 3.95x
BIIB
Biogen
27.78% 0.334 22.29% 0.68x
LLY
Eli Lilly and
68.61% 0.948 3.9% 0.63x
MRK
Merck &
46.15% 0.824 13.95% 0.88x
NVAX
Novavax
-47.39% 8.483 8.37% 0.85x
PFE
Pfizer
41.92% 0.516 40.56% 0.64x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
MRNA
Moderna
$1.3B -$70M -17.44% -17.44% 1.46% -$1.7B
BIIB
Biogen
$1.8B $496.4M 7.34% 10.52% 20.72% $805.6M
LLY
Eli Lilly and
$9.3B $4.4B 21.5% 66.4% 15.57% -$458.9M
MRK
Merck &
$12.6B $4B 15.67% 29.26% 26.54% $8.5B
NVAX
Novavax
$23.9M -$134M -- -- -139.74% -$146.8M
PFE
Pfizer
$12.4B $5.3B 2.66% 4.63% 31.06% $6.1B

Moderna vs. Competitors

  • Which has Higher Returns MRNA or BIIB?

    Biogen has a net margin of 0.7% compared to Moderna's net margin of 15.76%. Moderna's return on equity of -17.44% beat Biogen's return on equity of 10.52%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRNA
    Moderna
    72.29% $0.03 $11.9B
    BIIB
    Biogen
    74.1% $2.66 $22.7B
  • What do Analysts Say About MRNA or BIIB?

    Moderna has a consensus price target of $127.09, signalling upside risk potential of 87.39%. On the other hand Biogen has an analysts' consensus of $242.83 which suggests that it could grow by 62.56%. Given that Moderna has higher upside potential than Biogen, analysts believe Moderna is more attractive than Biogen.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRNA
    Moderna
    7 12 1
    BIIB
    Biogen
    13 15 0
  • Is MRNA or BIIB More Risky?

    Moderna has a beta of 1.582, which suggesting that the stock is 58.238% more volatile than S&P 500. In comparison Biogen has a beta of -0.081, suggesting its less volatile than the S&P 500 by 108.074%.

  • Which is a Better Dividend Stock MRNA or BIIB?

    Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moderna pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MRNA or BIIB?

    Moderna quarterly revenues are $1.9B, which are smaller than Biogen quarterly revenues of $2.5B. Moderna's net income of $13M is lower than Biogen's net income of $388.5M. Notably, Moderna's price-to-earnings ratio is -- while Biogen's PE ratio is 13.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.03x versus 2.27x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRNA
    Moderna
    3.03x -- $1.9B $13M
    BIIB
    Biogen
    2.27x 13.49x $2.5B $388.5M
  • Which has Higher Returns MRNA or LLY?

    Eli Lilly and has a net margin of 0.7% compared to Moderna's net margin of 8.48%. Moderna's return on equity of -17.44% beat Eli Lilly and's return on equity of 66.4%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRNA
    Moderna
    72.29% $0.03 $11.9B
    LLY
    Eli Lilly and
    81.02% $1.07 $45.4B
  • What do Analysts Say About MRNA or LLY?

    Moderna has a consensus price target of $127.09, signalling upside risk potential of 87.39%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 23.58%. Given that Moderna has higher upside potential than Eli Lilly and, analysts believe Moderna is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRNA
    Moderna
    7 12 1
    LLY
    Eli Lilly and
    15 6 0
  • Is MRNA or LLY More Risky?

    Moderna has a beta of 1.582, which suggesting that the stock is 58.238% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

  • Which is a Better Dividend Stock MRNA or LLY?

    Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.65% to investors and pays a quarterly dividend of $1.30 per share. Moderna pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios MRNA or LLY?

    Moderna quarterly revenues are $1.9B, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Moderna's net income of $13M is lower than Eli Lilly and's net income of $970.3M. Notably, Moderna's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 86.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.03x versus 17.62x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRNA
    Moderna
    3.03x -- $1.9B $13M
    LLY
    Eli Lilly and
    17.62x 86.08x $11.4B $970.3M
  • Which has Higher Returns MRNA or MRK?

    Merck & has a net margin of 0.7% compared to Moderna's net margin of 18.95%. Moderna's return on equity of -17.44% beat Merck &'s return on equity of 29.26%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRNA
    Moderna
    72.29% $0.03 $11.9B
    MRK
    Merck &
    75.51% $1.24 $82.7B
  • What do Analysts Say About MRNA or MRK?

    Moderna has a consensus price target of $127.09, signalling upside risk potential of 87.39%. On the other hand Merck & has an analysts' consensus of $128.73 which suggests that it could grow by 29.54%. Given that Moderna has higher upside potential than Merck &, analysts believe Moderna is more attractive than Merck &.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRNA
    Moderna
    7 12 1
    MRK
    Merck &
    16 7 0
  • Is MRNA or MRK More Risky?

    Moderna has a beta of 1.582, which suggesting that the stock is 58.238% more volatile than S&P 500. In comparison Merck & has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.746%.

  • Which is a Better Dividend Stock MRNA or MRK?

    Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.14% to investors and pays a quarterly dividend of $0.81 per share. Moderna pays -- of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend.

  • Which has Better Financial Ratios MRNA or MRK?

    Moderna quarterly revenues are $1.9B, which are smaller than Merck & quarterly revenues of $16.7B. Moderna's net income of $13M is lower than Merck &'s net income of $3.2B. Notably, Moderna's price-to-earnings ratio is -- while Merck &'s PE ratio is 20.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.03x versus 4.00x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRNA
    Moderna
    3.03x -- $1.9B $13M
    MRK
    Merck &
    4.00x 20.83x $16.7B $3.2B
  • Which has Higher Returns MRNA or NVAX?

    Novavax has a net margin of 0.7% compared to Moderna's net margin of -143.53%. Moderna's return on equity of -17.44% beat Novavax's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MRNA
    Moderna
    72.29% $0.03 $11.9B
    NVAX
    Novavax
    28.27% -$0.76 -$357.2M
  • What do Analysts Say About MRNA or NVAX?

    Moderna has a consensus price target of $127.09, signalling upside risk potential of 87.39%. On the other hand Novavax has an analysts' consensus of $16.00 which suggests that it could grow by 85.19%. Given that Moderna has higher upside potential than Novavax, analysts believe Moderna is more attractive than Novavax.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRNA
    Moderna
    7 12 1
    NVAX
    Novavax
    2 2 0
  • Is MRNA or NVAX More Risky?

    Moderna has a beta of 1.582, which suggesting that the stock is 58.238% more volatile than S&P 500. In comparison Novavax has a beta of 2.017, suggesting its more volatile than the S&P 500 by 101.749%.

  • Which is a Better Dividend Stock MRNA or NVAX?

    Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moderna pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MRNA or NVAX?

    Moderna quarterly revenues are $1.9B, which are larger than Novavax quarterly revenues of $84.5M. Moderna's net income of $13M is higher than Novavax's net income of -$121.3M. Notably, Moderna's price-to-earnings ratio is -- while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.03x versus 1.50x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRNA
    Moderna
    3.03x -- $1.9B $13M
    NVAX
    Novavax
    1.50x -- $84.5M -$121.3M
  • Which has Higher Returns MRNA or PFE?

    Pfizer has a net margin of 0.7% compared to Moderna's net margin of 25.23%. Moderna's return on equity of -17.44% beat Pfizer's return on equity of 4.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRNA
    Moderna
    72.29% $0.03 $11.9B
    PFE
    Pfizer
    70.27% $0.78 $159.2B
  • What do Analysts Say About MRNA or PFE?

    Moderna has a consensus price target of $127.09, signalling upside risk potential of 87.39%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.29%. Given that Moderna has higher upside potential than Pfizer, analysts believe Moderna is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRNA
    Moderna
    7 12 1
    PFE
    Pfizer
    8 13 1
  • Is MRNA or PFE More Risky?

    Moderna has a beta of 1.582, which suggesting that the stock is 58.238% more volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

  • Which is a Better Dividend Stock MRNA or PFE?

    Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.29% to investors and pays a quarterly dividend of $0.42 per share. Moderna pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

  • Which has Better Financial Ratios MRNA or PFE?

    Moderna quarterly revenues are $1.9B, which are smaller than Pfizer quarterly revenues of $17.7B. Moderna's net income of $13M is lower than Pfizer's net income of $4.5B. Notably, Moderna's price-to-earnings ratio is -- while Pfizer's PE ratio is 36.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.03x versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRNA
    Moderna
    3.03x -- $1.9B $13M
    PFE
    Pfizer
    2.56x 36.09x $17.7B $4.5B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Tesla Going to Buy Uber?
Is Tesla Going to Buy Uber?

Tesla has always been in the habit of making large,…

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

If you want to invest in an AI-leading tech company,…

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Sell
40
MSTR alert for Dec 24

MicroStrategy [MSTR] is down 8.7% over the past day.

Sell
26
NUTX alert for Dec 24

Nutex Health [NUTX] is up 9.77% over the past day.

Sell
48
VRNA alert for Dec 24

Verona Pharma PLC [VRNA] is up 7.96% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock